ATE411028T1 - Alpha-aed und beta-aed-regulierung der nukleartranskription, genregulierung und/oder genexpression - Google Patents

Alpha-aed und beta-aed-regulierung der nukleartranskription, genregulierung und/oder genexpression

Info

Publication number
ATE411028T1
ATE411028T1 AT03718054T AT03718054T ATE411028T1 AT E411028 T1 ATE411028 T1 AT E411028T1 AT 03718054 T AT03718054 T AT 03718054T AT 03718054 T AT03718054 T AT 03718054T AT E411028 T1 ATE411028 T1 AT E411028T1
Authority
AT
Austria
Prior art keywords
regulation
aed
present
gene expression
nuclear transcription
Prior art date
Application number
AT03718054T
Other languages
English (en)
Inventor
Roger M Loria
Original Assignee
Roger M Loria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roger M Loria filed Critical Roger M Loria
Application granted granted Critical
Publication of ATE411028T1 publication Critical patent/ATE411028T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03718054T 2002-03-21 2003-03-21 Alpha-aed und beta-aed-regulierung der nukleartranskription, genregulierung und/oder genexpression ATE411028T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36581702P 2002-03-21 2002-03-21

Publications (1)

Publication Number Publication Date
ATE411028T1 true ATE411028T1 (de) 2008-10-15

Family

ID=28454718

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718054T ATE411028T1 (de) 2002-03-21 2003-03-21 Alpha-aed und beta-aed-regulierung der nukleartranskription, genregulierung und/oder genexpression

Country Status (7)

Country Link
US (1) US20030181434A1 (de)
EP (1) EP1490069B1 (de)
AT (1) ATE411028T1 (de)
AU (1) AU2003222070A1 (de)
CA (1) CA2483258A1 (de)
DE (1) DE60324118D1 (de)
WO (1) WO2003080810A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912240A (en) 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641768A (en) * 1989-11-17 1997-06-24 Loria; Roger M. 5-androstene 3β, 17β diol for treatment
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
US5912240A (en) * 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
SE0100857D0 (sv) * 2001-03-13 2001-03-13 Tomas Hagstroem Treatment of tumors

Also Published As

Publication number Publication date
AU2003222070A1 (en) 2003-10-08
EP1490069A4 (de) 2006-08-02
AU2003222070A8 (en) 2003-10-08
EP1490069B1 (de) 2008-10-15
WO2003080810A3 (en) 2004-04-22
DE60324118D1 (de) 2008-11-27
CA2483258A1 (en) 2003-10-02
US20030181434A1 (en) 2003-09-25
EP1490069A2 (de) 2004-12-29
WO2003080810A2 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
Emken et al. Human-robot cooperative movement training: learning a novel sensory motor transformation during walking with robotic assistance-as-needed
Hedayatpour et al. Physiological and neural adaptations to eccentric exercise: mechanisms and considerations for training
Reardon Electroceuticals spark interest
Dunsky et al. Motor imagery practice in gait rehabilitation of chronic post-stroke hemiparesis: four case studies
BRPI0407694A (pt) métodos de usar células derivadas do tecido adiposo no tratamento de condições cardiovasculares
WO2003105744A3 (en) THERAPEUTIC EXERCISE METHOD AND SYSTEM FOR A PARALYZED AND NON-PARALYZED NEUROMUSCULOSKLELET TRAINING SYSTEM
Pais-Vieira et al. Embodiment comfort levels during motor imagery training combined with immersive virtual reality in a spinal cord injury patient
BRPI0519016A2 (pt) agente preventivo ou terapÊutico para distérbios do sono, uso de uma droga, e, mÉtodo para prevenÇço e/ou tratamento de distérbios do sono
van Mersbergen et al. Modulation of relative fundamental frequency during transient emotional states
Burke Crosstalk opposing view: Independent fusimotor control of muscle spindles in humans: there is little to gain.
ATE411028T1 (de) Alpha-aed und beta-aed-regulierung der nukleartranskription, genregulierung und/oder genexpression
Kaulmann et al. Stabilization of body balance with Light Touch following a mechanical perturbation: Adaption of sway and disruption of right posterior parietal cortex by cTBS
English et al. Self-assessments of standardized scalp massages for androgenic alopecia: survey results
Novak A magical moment in research translation: strategies for providing high intensity bimanual therapy
Vozniuk et al. Neuroprosthetic technology bioness (exorobot) in the process of restoring motor and vegetative-trophic disorders in central paresis of the upper limb
Pichiorri et al. An All-in-One BCI-supported motor imagery training station: Validation in a real clinical setting with chronic stroke patients
DENG et al. The music-motor intervention methods for speech perception and motor timing disorder of stuttering patients
Solomonow-Avnon et al. The dose and intensity matter for chronic stroke
García-Guadarrama et al. Design of a Portable Electric-Stimulation System to Reduce the Essential Tremor on the Hand
Fihudha Application of Murottal Al-Quran Therapy on The Hallucination Scores of Hearing Hallucination Patients in Dr. RM. Soedjarwadi Psychiatric Hospital Klaten
Widodo et al. The Effect of Kinesio Taping on Pain and Hand Function in Laundry Workers With Carpal Tunnel Syndrome
Lew et al. Stroke and neurodegenerative disorders: 3. Poststroke rehabilitation
Svanborg et al. Snoring causes OSA: sensory nervous lesions in the palate worsen over time in untreated snorers but not in CPAP-treated patients
Sanfilippo Is Yoga Sabotaging Your Sleep?: There can be unintended consequences to your practice. Here's how to ensure that doesn't happen.
Nidzelskyi Analysis of the results of the study of sound pronunciation in patients with prosthetics with complete removable dentures

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties